Promising Targets Oral Session
Moderated by 2024 ACNP Program Committee Co-Chairs Tracy Bale & Staci Bilbo
**Limited Recording:
- CPL’36, a PDE10A inhibitor, Demonstrated efficacy, Safety and Good Tolerability in the Treatment of Acute Exacerbation of Schizophrenia – Results from a Phase 2 Clinical Trial -Mikolaj Matloka's presentation is live only
Sun 3 PM - 5 PM.Grand Sonoran F